Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer (PRIMUS)
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer (PRIMUS)
Sponsor and Collaborators
Biothera
Contact
Terri Gaffney
513.579.9911 ext 2593
t.gaffney@medpace.com
Investigator
Biothera
ClinicalTrials.gov Identifier
NCT01309126